Review began 02/04/2023 review ended 02/09/2023 published 02/17/2023 © copyright

HIGHLIGHTS

• who: Report and colleagues from the Internal Medicine, University of Missouri Kansas City, Kansas City, USA Pathology, University of Missouri Kansas have published the Article: Review began 02/04/2023 Review ended 02/09/2023 Published 02/17/2023 u00a9 Copyright, in the Journal: (JOURNAL) of February/17,/2023
• what: More patient education by primary care physicians about the potential hepatotoxic side effects of musclebuilding substances (not approved by the FDA) may help reduce the number of future DILI cases secondary to SARMs.

SUMMARY

Drug-induced liver injury (DILI) accounts for . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.